Moyamoya Disease Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Moyamoya Disease Market Trends and Insights

Rising Diagnosis Through Advanced Neurovascular Imaging

Imaging quality determines how quickly clinicians can move from suspected symptoms to a confirmed diagnosis in the Moyamoya disease market. GE HealthCare received FDA 510(k) clearance in February 2026 for SIGNA Sprint with Freelium, SIGNA Bolt, and the SIGNA One workflow platform, which can support MRA and perfusion imaging protocols used for moyamoya disease^{[1]“GE HealthCare Achieves MRI Portfolio Milestone with FDA Clearances for Next-Generation SIGNA MRI Technology,” GE HealthCare Investor News, investor.gehealthcare.com}. Philips introduced the BlueSeal Horizon helium-free 3.0T MRI platform in November 2025 with clinical AI capabilities for neuroimaging workflows^{[2]“Philips Unveils BlueSeal Horizon, Industry’s First Helium-Free 3.0T MRI Platform,” Philips Press Release, acc.philips.com}. These systems can improve vessel visualization, shorten scans, and reduce infrastructure constraints for hospitals that need advanced imaging. Japan’s guidelines allow 1.5T or higher MRA to support bilateral definitive diagnosis, reducing reliance on invasive DSA referrals and increasing MRI use across a broader hospital base. Earlier identification can increase the number of patients assessed for surgery and long-term surveillance. This supports diagnostic activity across the Moyamoya disease market without changing the central role of specialist interpretation. The Moyamoya disease market benefits when high-quality imaging becomes available beyond major referral centers.

Higher Recognition of Pediatric and Adult Stroke Phenotypes

Pediatric moyamoya disease commonly presents with ischemic events, including transient ischemic attacks, infarcts, and cognitive decline, while adult onset is more often hemorrhagic, particularly after age 40. Recognition of this age-related pattern had been limited, which delayed referrals in both populations. China’s 2025 expert consensus and Japan’s 2025 guidelines formalized symptom-based screening pathways that can support earlier evaluation. A 2026 review found that asymptomatic disease still carried a risk of ischemic or hemorrhagic stroke and radiological progression during 2 years of follow-up. Broader surveillance can expand demand for imaging and preventive revascularization in the Moyamoya disease market. It also makes existing diagnosed-case counts less representative of the full population requiring monitoring.

Expansion of Specialist Revascularization Capacity

Treatment outcomes are closely associated with surgical experience and center capability in the Moyamoya disease market. Direct STA-MCA bypass has been associated with an annual adult stroke rate of 1.4%, compared with 5.6% for indirect bypass alone. A 2025 multicenter Chinese study reported that a standardized superficial temporal artery patency concept reduced 5-year stroke recurrence from 31.6% to 11.9%. These findings encourage referrals toward high-volume programs that can perform direct or combined procedures. Each new specialist center can create ongoing demand for diagnosis, surgery, and follow-up imaging. Capacity expansion therefore supports care access and sustained activity across the Moyamoya disease market. The Moyamoya disease market can retain this activity through repeat surveillance after surgery.

AI-Assisted MRA and Retinal Screening for Case Finding

Artificial intelligence is changing the first stage of the diagnostic process in the Moyamoya disease market. A deep-learning model using time-of-flight MRA maximum-intensity projections achieved an AUC of 0.990 and accuracy of 0.933 for automated disease identification ISMRM. A multicenter study using T2-weighted imaging found that a DenseNet model showed stronger sensitivity and specificity than SCNN, LeNet, VGG, and ResNet architectures for detecting moyamoya angiopathy. These methods can support case finding at sites that do not have extensive vascular imaging expertise. Japanese diagnostic imaging literature in 2025 described AI-supported vessel-wall imaging and perfusion analysis as part of the clinical workflow. A 2025 study also found that deep-learning reconstruction on 1.5T MRA could provide vascular visualization comparable to or better than conventional 3T imaging. These advances may reduce field-strength barriers to diagnosis and extend screening capacity.

Limited High-Level Evidence and Heterogeneous Treatment Guidelines

Moyamoya disease lacks the randomized controlled trial base that payers often use for standard reimbursement decisions. A multicenter North American retrospective study found symptomatic stroke rates of 11.6% after direct revascularization and 9.6% after indirect revascularization, without a statistically significant difference. The European Stroke Organisation noted that the quality of evidence for surgical decisions is limited compared with other cerebrovascular conditions^{[3]“European Stroke Organisation Guidelines on Moyamoya Angiopathy,” European Stroke Organisation, cervco.fr}. In the United States, there is no national or local coverage determination for revascularization, which leaves insurers to apply their own review criteria. This inconsistency can delay treatment and make referral patterns less predictable. It also limits access to adjunctive drugs and weakens incentives for large medical-management trials in the Moyamoya disease market.

High Surgical Complexity and Concentration of Expertise

Moyamoya bypass procedures require specialized neurosurgical skills that remain concentrated in relatively few academic centers. Postoperative hyperperfusion has occurred in 21.5% to 50% of cases, while perioperative ischemic stroke has ranged from 1.6% to 16%. A March 2025 review found lower probabilities of clinical improvement among patients treated within 3 months of their last stroke compared with those treated at 6 months or later. In the Middle East, Africa, and much of South America, the gap between diagnosis and access to a trained bypass surgeon can exclude identified patients from procedural care. The same limitation restricts adoption of intraoperative tools such as FLOW800 indocyanine green angiography and FFR pressure-wire systems. These constraints can limit expansion of the Moyamoya disease market even when diagnostic capacity improves.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Offering: Treatment Leads Revenue While Diagnosis Grows Faster

Treatment held 68.31% of the Moyamoya disease market share in 2025, supported by surgical revascularization as the established approach for symptomatic disease. Direct STA-MCA bypass has high procedural revenue intensity because it requires complex surgical care and supporting imaging. A 2026 cohort study found that modified extracranial-intracranial combined bypass produced stronger functional independence and hemodynamic restoration than indirect bypass in adults with ischemic disease. Medical management includes antiplatelet treatment, such as aspirin and cilostazol, and serves lower-acuity and postoperative populations at lower per-patient revenue. Rehabilitation and supportive care remain relevant for patients who require care for residual neurological or cognitive effects after treatment.

Diagnosis is projected to grow at a 6.38% CAGR from 2026 to 2031, making it the fastest-growing offering. DSA remains the reference test for complex or unilateral cases, while MRA and CT angiography are gaining use as image interpretation improves. SPECT, PET, ASL-MRI, and transcranial Doppler ultrasound support preoperative hemodynamic evaluation and postoperative surveillance. This layered workflow can create repeat imaging demand over extended follow-up periods. Radiation concerns for CTA and DSA, especially in children, are encouraging greater use of MRI-based options. This supports the diagnostic side of the Moyamoya disease industry while preserving DSA for cases that require detailed vascular assessment. The Moyamoya disease market can therefore gain from both advanced and lower-field MRI pathways.

By Patient Demographic: Adults Anchor Revenue While Pediatric Care Expands

Adult patients accounted for 55.44% of revenue in 2025. Their position reflects the higher hospitalization intensity of adult disease, including hemorrhagic presentations that are more common after age 40. The adult age distribution peaks between 35 and 39 years in East Asia and in the sixth decade in Western populations. This pattern supports continued adult revenue concentration in the Moyamoya disease market. Pregnant and postpartum patients also require individualized antiplatelet and revascularization planning because of their elevated ischemic risk during gestation. These patients create focused demand at tertiary obstetric-neurology centers.

Pediatric patients are forecast to grow at a 7.52% CAGR from 2026 to 2031. Japan’s 2025 guidelines formalized symptom-based screening for childhood stroke, supporting earlier assessment at first presentation. A 2024 randomized trial reported benefit from remote ischemic conditioning before revascularization in pediatric disease. Earlier intervention extends the duration of imaging and follow-up monitoring for each patient. The others category includes secondary disease associated with sickle cell disease, Down syndrome, and neurofibromatosis type 1. Genetic screening programs that include RNF213 testing can identify some of these populations earlier.

By Clinical Presentation: Ischemic Care Leads While Hemorrhagic Referrals Rise

Ischemic presentation held 68.24% of revenue in 2025. Transient ischemic attacks and ischemic strokes are the main initial phenotype globally, especially among children and younger adults. Treatment pathways usually include antiplatelet care followed by elective revascularization after hemodynamic stabilization. This sequence supports a predictable cycle of diagnostic and procedural activity. Seizures and transient ischemic attacks can overlap with wider neurological triage. Cognitive and neurodevelopmental impairment is also increasingly recognized in pediatric care and adds demand for neuropsychological assessment.

Hemorrhagic presentation is projected to grow at a 7.22% CAGR from 2026 to 2031. The Japan Adult Moyamoya Trial showed that bypass surgery reduced rebleeding risk in hemorrhagic patients, which is supporting surgical referrals for this group. A 2026 editorial identified periventricular anastomosis as a key pathological factor in hemorrhagic disease. Preoperative assessment of these fragile collateral vessels through advanced MRI could become a routine workflow element. Combined revascularization reduced 5-year rebleeding from 31.6% to 11.9% in a 2025 multicenter study. This pattern supports demand for surgical instruments, hemostatic devices, and intraoperative imaging in the Moyamoya disease market.

By End User: Hospitals Hold Volume While Specialist Centers Grow Fastest

Hospitals held 51.56% of end-user revenue in 2025. They remain the main setting for complex revascularization, intensive postoperative monitoring, and acute stroke admissions. Academic medical centers, including Tongji Hospital, Beijing Tiantan Hospital, and Vanderbilt University Medical Center, concentrate clinical volume and influence treatment protocols. Vanderbilt is sponsoring a prospective trial on biomarker-led optimization of surgical outcomes that enrolls 100 patients with a 6-year follow-up period. Diagnostic imaging centers and rehabilitation centers generate smaller but recurring activity through surveillance imaging and postoperative neurological rehabilitation. Their services can continue for months or years after surgery.

Specialized neurology and neurosurgery centers are forecast to grow at a 7.95% CAGR from 2026 to 2031. These centers are investing in dedicated programs, intraoperative imaging tools, and postoperative perfusion imaging suites. FLOW800 indocyanine green video angiography and FFR pressure-wire systems are among the tools used in this setting. Ambulatory surgical centers are entering lower-complexity care, especially for indirect bypass procedures. U.S. stroke-center accreditation standards reinforce specialist center growth by directing complex cerebrovascular cases toward settings that meet defined quality benchmarks. This shift can increase the value of specialized facilities across the Moyamoya disease market.

Geography Analysis

North America held 38.61% of revenue in 2025. The region’s position is supported by high per-procedure spending, with average hospitalization costs of USD 133,754 per case reported in the United States. The FY2026 ICD-10-CM designation I67.5 provides a billable code for moyamoya disease, which supports more consistent diagnostic coding. Canada’s universal coverage supports revascularization for qualifying patients through provincial programs. Mexico has more limited public infrastructure, creating a two-tier regional pattern. Vanderbilt’s prospective biomarker study also reflects North America’s role in generating data that can influence care protocols. The Moyamoya disease market in the region benefits from this concentration of clinical and reimbursement infrastructure.

Asia-Pacific is forecast to grow at a 7.65% CAGR from 2026 to 2031 and has the highest disease burden. Japan reported prevalence of 10.5 per 100,000 and South Korea reported 16.1 per 100,000, while China reported 3.92 per 100,000 across a much larger population. Japan’s 2025 guidelines allow MRA-based diagnosis without mandatory DSA in bilateral cases. China’s 2025 expert consensus similarly supports standardized care across its expanding tertiary hospital network. India, South Korea, and Australia can benefit as neurosurgical training and advanced imaging capacity increase. A Korean study found a 1.08% RNF213 p.Arg4810Lys allele frequency in healthy participants, indicating a pool of people who may be identified through systematic screening.

Europe, the Middle East and Africa, and South America remain the emerging edge of the Moyamoya disease market. The European Stroke Organisation found that disease is likely underdiagnosed outside East Asia, with Western European incidence of 0.047 to 0.086 per 100,000. Germany, France, and the United Kingdom are the main European specialist hubs, while Italy and Spain are developing referral networks. Saudi Arabia and the United Arab Emirates are expanding advanced neurosurgical capacity, and South Africa remains the regional hub for complex cerebrovascular surgery. Limited specialist density continues to constrain scale across much of sub-Saharan Africa and South America. Wipro GE HealthCare launched the SIGNA Prime Elite, an AI-powered MRI system made in India, in January 2026 to expand imaging access in price-sensitive settings.